All In Biotech

Drug Trial Radar · NCT00487994

Safety and Efficacy of Lapaquistat Acetate Taken Alone and With Atorvastatin in Subjects With Primary Dyslipidemia

A Double-Blind, Randomized, Parallel Group Study to Evaluate the Safety, Tolerability and Efficacy of Lapaquistat Acetate Alone or Coadministered With Atorvastatin in Subjects With Primary Dyslipidemia

Last checked: Nov 19, 2026Latest source record: May 24, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 2,130 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,130

Actual

Start

Nov 2004

Primary completion

May 2007

Study completion May 2007

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Jun 19, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the overall safety of Lapaquistat Acetate, once daily (QD), by itself or in combination with atorvastatin in subjects with primary dyslipidemia.

Conditions

  • Dyslipidemia

Interventions

  • Lapaquistat acetateDrug

    Lapaquistat acetate 100 mg, tablets, orally, once daily and Atorvastatin placebo-matching capsules, orally, once daily for up to 96 weeks.

  • Lapaquistat acetate and atorvastatinDrug

    Lapaquistat acetate 100 mg, tablets, orally, once daily and Atorvastatin 10 mg, capsules, orally, once daily for up to 96 weeks.

  • AtorvastatinDrug

    Lapaquistat acetate placebo-matching tablets, orally, once daily and Atorvastatin 10 mg, capsules, orally, once daily for up to 96 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Lens Opacity Classification System findingsTime frame: Weeks 24, 48, 72, and 96 or Final Visit
  2. Best corrected visual acuityTime frame: Weeks 24, 48, 72, and 96 or Final Visit
  3. Adverse EventsTime frame: Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96 or Final Visit
  4. Clinical Laboratory TestsTime frame: Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96 or Final Visit
  5. Vital signs (blood pressure and pulse rate) and weightTime frame: Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96 or Final Visit
  6. 12-lead ElectrocardiogramTime frame: Weeks 48 and 96 or Final Visit
  7. Physical ExaminationTime frame: Weeks 48 and 96 or Final Visit

Locations

128 sites in 17 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Mobile, Alabama

  • Site not named

    Northport, Alabama

  • Site not named

    Chandler, Arizona

  • Site not named

    Phoenix, Arizona

  • Site not named

    Sierra Vista, Arizona

  • Site not named

    Jonesboro, Arkansas

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Anaheim, California

  • Site not named

    Rancho Cucamonga, California

  • Site not named

    Santa Rosa, California

  • Site not named

    Golden, Colorado

  • Site not named

    Coral Gables, Florida

  • Site not named

    Fort Myers, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Sarasota, Florida

  • Site not named

    West Palm Beach, Florida

  • Site not named

    Dunwoody, Georgia

  • Site not named

    Boise, Idaho

  • Site not named

    Idaho Falls, Idaho

  • Site not named

    Arlington Heights, Illinois

  • Site not named

    Chicago, Illinois

  • Site not named

    Elk Grove Village, Illinois

  • Site not named

    Evansville, Indiana

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Waterloo, Iowa

  • Site not named

    Kansas City, Kansas

  • Site not named

    Overland Park, Kansas

  • Site not named

    Louisville, Kentucky

  • Site not named

    New Orleans, Louisiana

  • Site not named

    Flint, Michigan

  • Site not named

    Edina, Minnesota

  • Site not named

    St Louis, Missouri

  • Site not named

    Omaha, Nebraska

  • Site not named

    Ship Bottom, New Jersey

  • Site not named

    Rochester, New York

  • Site not named

    Syracuse, New York

  • Site not named

    Charlotte, North Carolina

  • Site not named

    Statesville, North Carolina

  • Site not named

    Wilmington, North Carolina

Showing 40 of 128 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.